florbetapir

a PET agent for Abeta plaques; structure in first source

Also Known As:

18F-AV-45; 2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-5-(4-methylaminostyryl)pyridine; 4-(2-(6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzamide; Amyvid; florbetapir F 18; florbetapir F18

Networked: 283 relevant articles (3 outcomes, 67 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - florbetapir: 283
- Alcohols: 595
  - Glycols: 38
    - Ethylene Glycols: 8
      - florbetapir: 283

Experts

1.	Alzheimer’s Disease Neuroimaging Initiative: 34 articles (10/2021 - 01/2013)
2.	Alzheimer's Disease Neuroimaging Initiative: 33 articles (07/2022 - 10/2012)
3.	Mintun, Mark A: 24 articles (01/2021 - 01/2011)
4.	Pontecorvo, Michael J: 22 articles (01/2021 - 06/2010)
5.	Joshi, Abhinay D: 21 articles (01/2021 - 06/2010)
6.	Jagust, William J: 18 articles (10/2021 - 10/2012)
7.	Skovronsky, Daniel M: 16 articles (01/2016 - 06/2010)
8.	Landau, Susan M: 15 articles (10/2021 - 10/2012)
9.	Chen, Kewei: 14 articles (01/2019 - 11/2011)
10.	Fleisher, Adam S: 12 articles (01/2021 - 01/2011)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/2023 - "Positron emission tomography (PET) with fluorodeoxyglucose (FDG) or florbetapir (AV45) has been proved effective in the diagnosis of Alzheimer's disease. " 01/01/2021 - "Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study." 01/01/2016 - "The current study adopted a weighted multi-modality sparse representation-based classification method to combine data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, from three imaging modalities: Volumetric magnetic resonance imaging (MRI), fluorodeoxyglucose (FDG) positron emission tomography (PET), and florbetapir PET. " 06/01/2012 - "The purpose of this study was to determine how clinical interpretations of the (18)F-amyloid tracer florbetapir compares diagnostically with (18)F-FDG PET when evaluating patients with Alzheimer disease (AD) and controls. " 01/01/2023 - "We included 50 HCs and 109 aMCI patients from the Alzheimer's Disease Neuroimaging Initiative phase 2/GO based on availability of baseline T1-weighted magnetic resonance imaging, 18 F-florbetapir positron emission tomography (PET), and 18 F-fluorodeoxyglucose (FDG) PET. "
2.	Cognitive Dysfunction 10/01/2014 - "This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. " 12/15/2022 - "This study aimed to explore sTREM2 as a central and peripheral predictor of the conversion from mild cognitive impairment (MCI) to AD.METHODSsTREM2 and Aβ1-42 levels in cerebrospinal fluid (CSF) and florbetapir-PET (AV45) images were analyzed for healthy control (HCs), patients with MCI, and patients with AD from the ADNI database. " 07/01/2016 - "Five participants with PDD had florbetapir(18F) PET imaging prior to death as a part of a longitudinal research study of cognitive decline in PD. " 01/01/2016 - "The study included asymptomatic, cognitively normal (CN) controls and patients with early mild cognitive impairment (MCI), late MCI, and AD, all with significant levels of cortical Aβ based on their florbetapir PET scans to restrict the study to patients truly in the AD continuum. " 04/01/2012 - "The aim of this study was to test the feasibility of using PET imaging with (18)F-AV-45 (florbetapir) in a routine clinical environment to differentiate between patients with mild to moderate AD and mild cognitive impairment (MCI) from normal healthy controls (HC). "
3.	Disease Progression 06/01/2015 - "Scenario analysis was applied to explore outcomes under different conditions, which included: (i) use of florbetapir-PET earlier in disease progression (MMSE score=22); and (ii) the addition of fluorodeoxyglucose (FDG)-PET to SCE. " 01/01/2018 - "The clinical course, changes in cognitive function, brain magnetic resonance imaging (MRI) and 18F-AV-45 PET scan were investigated in FAD patients and sporadic AD (sAD) patients. " 01/01/2022 - "In conclusion, the tracer-specific reference tissue improved the detection of 18 F-FDG, 18 F-florbetapir, and 18 F-flortaucipir PET SUVR changes, which helps the early diagnosis, monitoring of disease progression, and therapeutic response in Alzheimer's disease."
4.	Dementia (Dementias) 01/01/2023 - "Participants included 136 ADNI dementia-free participants with 2 florbetapir positron emission tomography (PET) scans. " 10/01/2022 - "In 2011-2013, dementia-free participants underwent brain magnetic resonance imaging (with white matter hyperintensity [WMH] and brain volume measurement) and florbetapir (Aβ) positron emission tomography. " 01/01/2020 - "Neither global nor regional [18F]florbetapir SUVR concentrations predicted progression to dementia. " 09/05/2017 - "We analyzed 595 older adults without dementia classified cross-sectionally as Aβ- (n = 325) and Aβ+ (n = 270) using longitudinal florbetapir PET. " 06/01/2014 - "We present 2 cases combining the new hybrid imaging modality PET/MRI, which offers molecular and morphological information, with F-florbetapir in the differential diagnosis of dementia. "
5.	Atherosclerosis 12/01/2019 - "Methods- Three hundred six nondemented participants from the ARIC study (Atherosclerosis Risk in Communities Study) underwent florbetapir positron emission tomography and 2D echocardiography (echo). " 10/01/2023 - "From 2012 to 2014, the ARIC-PET (Atherosclerosis Risk in Communities - Positron Emission Tomography) ancillary recruited 322 nondemented ARIC participants who completed 3T brain magnetic resonance imaging with T2*GRE as part of ARIC visit 5 to undergo florbetapir positron emission tomography imaging. " 12/15/2020 - "Methods and Results A total of 316 dementia-free participants from the ARIC (Atherosclerosis Risk in Communities) study underwent florbetapir positron emission tomography, electrocardiography, and 2-dimensional echocardiography. " 01/01/2020 - "The Atherosclerosis Risk in Communities-Positron Emission Tomography (ARIC-PET) study is a prospective cohort study of 346 participants without dementia who underwent florbetapir PET imaging. " 01/01/2020 - "Of 346 adults without dementia aged 70 to 90 years who were sequentially recruited from 3 of 4 sites of the larger Atherosclerosis Risk in Communities study into a study of brain florbetapir positron emission tomography (ARIC-PET), 300 met inclusion criteria. "

Related Drugs and Biologics

1.	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indole
2.	Amyloid (Amyloid Fibrils)
3.	florbetapir
4.	Biomarkers (Surrogate Marker)
5.	Amyloid beta-Peptides
6.	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbene
7.	flutemetamol
8.	Apolipoproteins E (ApoE)
9.	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)
10.	Fluorine

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Investigational Therapies (Experimental Therapy)
3.	Heart Transplantation (Grafting, Heart)
4.	Intravenous Injections
5.	Intravenous Administration